$SRNE My best educated guess: The buyout offer is a byproduct of the recent Shanghai conference, but our folks were there to work on a partnership. I expect news on that front to coincide with ASH and Longwood (Dec. 7-10), followed w/in weeks by a 9-figure arbitration settlement. All of which is just a precursor to mostly encouraging clinical trial data in 2020. I’ll continue to add at what I believe are bargain prices. I could be wrong.